CureDuchenne is the nation’s leading nonprofit organization dedicated to funding a cure for Duchenne, the most common and lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys living today. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy.
With a mission to cure Duchenne muscular dystrophy, CureDuchenne breaks the traditional charitable mold and balances passion with business acumen. Our innovative venture philanthropy model funds groundbreaking research, early diagnosis and treatment access. With pioneering education and support programs, our organization drives real change for those with Duchenne muscular dystrophy and their loved ones.
Join us at a free Workshop or Session near you!
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Connect With CureDuchenne
Patient Worthy Posts on Duchenne Muscular Dystrophy
A new precision medicine center, specifically for pediatrics, has launched in Utah. This new center is the result of collaborative efforts from the Intermountain Primary
Researchers at the University of Pennsylvania are working on a new potential gene therapy for Duchenne muscular dystrophy (DMD). DMD is a rare form of
Two Nonprofits Award $200,000 Grant for Development of Duchenne Muscular Dystrophy Patient Reported Outcomes
According to a story from PR Newswire, the nonprofit groups Duchenne UK and Parent Project Muscular Dystrophy (PPMD) have jointly awarded grant funding to the
According to a story from BioSpace, a global collaborative called the Trajectory Analysis Project recently released a study that utilized the North Star Ambulatory Assessment
According to a story from 10tv.com, Kelly Maynard could be hear cheering loudly from the sidelines as her son Jackson, aged 12, scored a touchdown
The accelerated approval granted by the FDA for the Duchenne muscular dystrophy drug eteplirsen, developed by Sarepta Therapeutics, was granted only after internal disagreements